A new approach based on CXCR4-targeted combination liposomes for the treatment of liver fibrosis

Author:

Ullah Aftab1,Chen Gang2,Yibang Zhang1,Hussain Abid34,Shafiq Muhammad5ORCID,Raza Faisal6ORCID,Liu Daojun5,Wang Kaikai7ORCID,Cao Jin1,Qi Xueyong1

Affiliation:

1. College of Pharmaceutical Science, Jiangsu University, Zhenjiang, Jiangsu 212013, China

2. Institute of Comparative Medicine, College of Veterinary Medicine, Yangzhou University, Yangzhou 225009, Jiangsu, China

3. School of Life Science, Advanced Research Institute of Multidisciplinary Science, Institute of Engineering Medicine, Key Laboratory of Molecular Medicine and Biotherapy, Beijing Institute of Technology, Beijing, 100081, China

4. Chinese Academy of Sciences (CAS) Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety, CAS Center for Excellence in Nanoscience, National Center for Nanoscience and Technology of China, Beijing 100190, China

5. Department of Pharmacy, Shantou University Medical College, 22 Xinling Road, Shantou 515041, Guangdong, China

6. School of Pharmacy, Shanghai Jiaotong University, Shanghai 200240, Shanghai, China

7. School of Pharmacy, Nantong University, Nantong 226001, China

Abstract

We propose a chemokine receptor 4 (CXCR4)-targeted combination (CTC) liposomal therapy to treat carbon tetrachloride (CCl4)-induced liver fibrosis. CTC lipo reverses the liver fibrosis to normalization.

Funder

Li Ka Shing Foundation

Shantou University Medical College

Publisher

Royal Society of Chemistry (RSC)

Subject

General Materials Science,Biomedical Engineering

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3